Sanofi India Limited's Board of Directors has greenlit an exclusive distribution and promotion agreement between SIL and Emcure Pharmaceuticals Limited (Emcure) for SIL’s Cardiovascular products in India, effective immediately.

Under this agreement, Emcure Pharmaceuticals will assume the exclusive distribution and promotional responsibilities for Sanofi India's Cardiovascular (CV) range of products, which include renowned brands such as Cardace, Clexane, Targocid, Lasix, and Lasilactone.

While Sanofi India will retain ownership, importation, and manufacturing of these brands across its plants in India and internationally, Emcure will leverage its expertise to engage healthcare professionals and broaden the accessibility of these therapeutic solutions to patients across all regions of India.

Employees from Sanofi India involved in the concerned operations will have the opportunity to transition to Emcure Pharmaceuticals.

Rodolfo Hrosz, Managing Director of Sanofi India Limited, emphasized, “Sanofi is dedicated to enhancing the lives of patients in India through its diverse range of products. Sanofi India boasts several cardiovascular products that are leaders in their respective categories. Through our partnership with Emcure, which boasts a widespread presence across India, we aim to mutually benefit healthcare professionals and patients by maximizing the reach of our CV products.”

Satish Mehta, Chief Executive Officer and Managing Director of Emcure Pharmaceuticals Limited, expressed his enthusiasm, stating, “At Emcure Pharmaceuticals, our competitive edge lies in our established presence across all major therapeutic areas, including cardiology. We are thrilled to collaborate with Sanofi India, as their esteemed range of cardiovascular brands will complement our robust CV portfolio, resulting in a highly formidable offering. In line with this initiative, relevant teams from Sanofi also have the opportunity to join us.”

Sanofi is poised to invigorate its business in the country through an accelerated growth plan, 'India for India', spanning its pharmaceuticals, specialty, consumer healthcare, and vaccines divisions.